Sander Dale A.'s Form 4 filing
Humacyte, Inc. (HUMA) · filed Aug 29, 2024
- Accession no.
- 0001818382-24-000165
- Filed
- Aug 29, 2024
- Trade date
- Aug 27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $263.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sander Dale A.CIK 0001878193 | Officer (CFO and Chief Corp. Deve. Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2024 | Common Stock | MOption exerciseAcquired | +39,389 | $2.56 | +$100,835.84 | 41,389 | Direct | |
| Aug 27, 2024 | Common Stock | SSaleDisposed | −39,389 | $6.68F1 | −$263,118.52 | 2,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2024 | Common Stock | MOption exerciseDisposed | −39,389 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.